



Introducing Australia's new 4-factor prothrombin complex concentrate products BERIPLEX®¹

PROTHROMBINEX®-VF
Human Prothrombin Complex

Available until mid 2024



Scan for approved Product Information on PROTHROMBINEX®-VF



Beriplex® P/N
Prothrombin Complex Concentrate

Available temporarily from mid 2024



Scan for approved Product Information on BERIPLEX® P/N



Beriplex® AU
Prothrombin Complex Concentrate

Available from late 2024/early 2025



FOR HEALTHCARE PROFESSIONALS. BEFORE PRESCRIBING, PLEASE REVIEW PRODUCT INFORMATION AVAILABLE AT <https://www.cslbehring.com.au/products/products list>

Australia's Plasma

Global Process

Product Characteristics Card³⁻⁴

Differences	PROTHROMBINEX®-VF ²	BERIPLEX® P/N 500 IU ³	BERIPLEX® AU 500 IU ⁴
Presentations	500 IU		
Active ingredients	Factor IX (500 IU) Factor II (approx. 500 IU) Factor X (approx. 500 IU)	Factor II (400–960 IU) Factor VII (200–500 IU) Factor IX (400–620 IU) Factor X (440–1200 IU) Protein C (300–900 IU) Protein S (240–760 IU)	
Dosing	Dosing differences between PROTHROMBINEX®-VF and BERIPLEX® include the dosing algorithm (initial International Normalised Ratio (INR) ranges, target INR and related dose), maximum single dose by INR range and inclusion of dosing in mL/kg body weight.		
Rate of administration	Approximately 3 mL per minute or as tolerated by patient	Not exceeding 3 IU/kg body weight/minute, max. 210 IU/minute, approximately 8 mL per minute	
Storage conditions	Store 2–8°C (<i>do not freeze</i>) Can be stored below 25°C for a single period of 6 months	Store below 25°C (<i>do not freeze</i>)	
Shelf life	3 years		
Plasma source	Australia	International	Australia
Estimated available date	Until mid 2024	From mid 2024	From late 2024/early 2025*

* Variation to manufacture using Australian plasma pending regulatory approval.

These products are funded under arrangements implemented by the National Blood Authority. Please refer to the National Blood Authority for details www.blood.gov.au

Before prescribing, please review Product Information available at <https://cslbehring.com.au/products/products-list>

References: 1. National Blood Authority. Update on the transition of PROTHROMBINEX-VF (prothrombin complex concentrate). Available at: <https://blood.gov.au/update-transition-prothrombinex-vf-prothrombin-complex-concentrate-0>. Accessed: 6 March 2024. 2. PROTHROMBINEX®-VF Approved Product Information. 3. BERIPLEX® P/N Approved Product Information. 4. BERIPLEX® AU Approved Product Information.

PROTHROMBINEX® and BERIPLEX® are registered trademarks of CSL Group of Companies. Copyright© 2024. All rights reserved.

For Medical/Technical Inquiries: Phone: 1800 642 865 Email: medicalinformation@cslbehring.com.au

For Customer Service Inquiries: Phone: 1800 063 892 Email: customerservice@cslbehring.com.au Internet: www.cslbehring.com.au

CSL Behring (Australia) Pty Ltd. 655 Elizabeth Street, Melbourne, Victoria, Australia, 3000. ABN: 48 160 734 761. AU-PTX-0006. CSB8423. June 2024.



Australian Red Cross
Lifeblood®

This product is made possible through the generosity of Australia's voluntary blood and plasma donors.

CSL Behring